Aktuelle Neurologie 2002; 29(10): 513-515
DOI: 10.1055/s-2002-36018
Aktuelle Kontroverse
© Georg Thieme Verlag Stuttgart · New York

„Early ischemic signs” haben keine prädiktive Aussage für den Erfolg und die Komplikationsrate der systemischen Thrombolyse

Early Ischemic Signs Predict Neither Success Nor Complications of Intravenous ThrombolysisG.  F.  Hamann1 , J.  Röther2
  • 1Neurologische Klinik, Ludwig-Maximilians-Universität, Klinikum, Standort Großhadern, München
  • 2Neurologische Klinik, Universitätsklinikum Eppendorf, Hamburg
Further Information

Publication History

Publication Date:
09 December 2002 (online)

Zusammenfassung

Die in Deutschland weitgehend strikte Beachtung von > 33 % early ischemic signs (EIC) im Territorium der mittleren Hirnarterie im CCT als Ausschlusskriterium für die intravenöse Lysebehandlung des akuten Mediainfarktes beruht im Wesentlichen auf den beiden ECASS-Studien. Beide Studien waren bekanntlich negativ bezüglich des Effektes der Lysebehandlung. Die bisher einzig positive systemische Lysestudie, die NINDS-Studie, benützte das CCT nur zum prospektiven Blutungsausschluss. EIC wurden nicht prospektiv ausgewertet. Eine post-hoc-Analyse der Daten der NINDS-Studie bezüglich der EIC ergab, dass diese keine prädiktive Bedeutung für den Erfolg noch die Komplikationen hatten. Im Gegenteil hatten Patienten mit EIC > 33 % besonders von der Lyse profitiert. In diesem Beitrag werden die Argumente gesammelt, dass auch in Deutschland Patienten innerhalb des 3-h-Zeitfensters nicht von der intravenösen Lyse alleinig aufgrund von CCT-Kriterien ausgeschlossen werden.

Abstract

Early ischemic changes (EIC) on the initial CCT which involve more than 33 % of the territory of the middle cerebral artery (MCA) are currently used in Germany as exclusion criteria for the application of intravenous thrombolysis. These criteria were adopted on the basis of two ECASS studies, both of which were negative as regards any therapeutic effect of intravenous thrombolysis. The only positive thrombolysis study conducted so far, the NINDS- rt-PA trial, used CCT only to prospectively exclude intracerebral hemorrhage; it did not evaluate any EIC. A recent post-hoc analysis of the NINDS-rt-PA trial as regards EIC concluded that these subtle signs had no predictive value as regards success or complications of thrombolysis. However, the study also showed that patients with EIC > 33 % of the MCA territory had benefitted the most from the treatment. This article summarizes the evidence for changing the current treatment rules in Germany so that no acute stroke patient (within 3 hours of symptom begin) is excluded from intravenous thrombolysis on the basis of only CCT criteria.

Literatur

  • 1 Patel S C, Levine S R, Tilley B C. et al . Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.  JAMA. 2001;  286 2830-2838
  • 2 The NINDS rt-PA Stroke Study Group . Tissue plasminogen activator or acute ischemic stroke.  N Engl J Med. 1995;  333 1581-1587
  • 3 Chiu D, Krieger D, Villar-Cordova C. et al . Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice.  Stroke. 1998;  29 18-22
  • 4 Katzan I L, Furlan A J, Lloyd L E. et al . Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.  JAMA. 2000;  283 1151-1158
  • 5 Lopez-Yunez A M, Bruno A, Williams L S. et al . Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebra hemorrhage.  Stroke. 2001;  32 12-16
  • 6 Hacke W, Kaste M, Fieschi C. et al . Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).  JAMA. 1995;  274 1017-1025
  • 7 Hacke W, Kaste M, Fieschi C. et al . Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II).  Lancet. 1998;  352 1245-1251
  • 8 Steiner T, Bluhmki E, Kaste M. et al . The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study.  Cerebrovasc Dis. 1998;  8 198-203
  • 9 Furlan A, Higashida R, Wechsler L. et al . Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism.  JAMA. 1999;  282 2003-2011
  • 10 Roberts H C, Dillon W P, Furlan A J. et al . Computed tomographic findings in patients undergoing intra-arterial thrombolysis for acute ischemic stroke due to middle cerebral artery occlusion: results from the PROACT II trial.  Stroke. 2002;  33 1557-1565
  • 11 Hacke W. Position of the German Society of Neurology on limited approval of rt-PA for treatment of acute ischemic stroke.  Nervenarzt. 2001;  72 477-478
  • 12 von Kummer R, Bourquain H, Bastianello S. et al . Early prediction of irreversible brain damage after ischemic stroke at CT.  Radiology. 2001;  219 95-100
  • 13 Kucinski T, Koch C, Grzyska U. et al . The predictive value of early CT and angiography for fatal hemispheric swelling in acute stroke.  Am J Neuroradiol. 1998;  19 839-846
  • 14 Saur D, Kucinski T C, Grzyska U. et al . Sensitivity and interrater agreement of CCT and DWI in acute stroke.  Cerebrovasc Dis. 2002;  13 (Suppl 3) 101
  • 15 Grotta J C, Chiu D, Lu M. et al . Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy.  Stroke. 1999;  30 1528-1533
  • 16 Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study.  Stroke. 1997;  28 957-960
  • 17 Larrue V, von Kummer R, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australian Acute Stroke Study (ECASS II).  Stroke. 2001;  32 438-441
  • 18 Hamann G F, del Zoppo G J, von Kummer R. Hemorrhagic transformation of cerebral infarction-possible mechanisms.  Thromb Haemost. 1999;  82, Suppl 92-94
  • 19 Hamann G F, Liebetrau M, Martens H. et al . Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat.  J Cereb Blood Flow Metab. 2002;  22 526-533
  • 20 del Zoppo G J, von Kummer R, Hamann G F. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke.  J Neurol Neurosurg Psychiatry. 1998;  65 1-9
  • 21 Röther J, Schellinger P D, Gass A. et al .Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke < 6 h. Stroke 2002, in press

Prof. Dr. med. Gerhard F. Hamann

Neurologische Klinik · Ludwig-Maximilians-Universität · Klinikum der Universität, Standort Großhadern

Marchioninistraße 15

81377 München

Email: hamann@brain.nefo.med.uni-muenchen.de

    >